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Background: Schistosoma mansoni infection represents a major cause of morbidity and mortality in many areas
of the developing world. Effective vaccines against schistosomiasis are not available and disease management
relies mainly on treatment with the anthelmintic drug praziquantel. Several promising schistosomal antigens
have been evaluated for vaccine efficacy such as Sm14, Sm29 and tetraspanins. However, most investigators
examine these promising antigens in animal models individually rather than in properly adjuvanted antigen
combinations.
Methods: In the present study, we made a recombinant fusion protein comprised of the promising
schistosomal antigens Sm14 and Sm29. The fusion protein, FSm14/29, was administered to Swiss albino mice
either unadjuvanted or adjuvanted with polyinosinic-polycytidylic acid adjuvant, poly(I:C). Mice were challenged
with S. mansoni cercariae and different parasitological/immunological parameters were assessed seven weeks
post-challenge. Data were analyzed using the ANOVA test with post-hoc Tukey-Kramer test.
Results: Mice pre-immunized with unadjuvanted or poly(I:C)-adjuvanted fusion protein showed reduction of
adult worm burden of 44.7 and 48.4%, respectively. In addition, significant reduction of tissue egg burdens was
observed in mice immunized with the fusion protein when compared with the infected saline/adjuvant negative
control groups and groups immunized with the individual Sm14 and Sm29 antigens. Light microscope and
scanning electron microscope (SEM) investigation of adult worms recovered from FSm14/29-immunized mice
revealed appreciable morphological damage and tegumental deformities. Histopathological examination of liver
sections of immunized mice demonstrated reduced granulomatous and inflammatory reactions when compared
with infected unvaccinated mice or mice immunized with the individual Sm14 and Sm29 antigens.
Conclusion: The findings presented in this study highlight the importance of the fusion protein FSm14/29 as a
potential vaccine candidate that is worthy of further investigation.
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Schistosomiasis is considered to be one of the most ser-
ious parasitic infections in the world. It is estimated to
infect more than 207 million in at least 74 countries
worldwide [1]. The use of the anthelmintic drug prazi-
quantel for treatment is the cornerstone of managing
the disease in infected individuals. However, there are
high re-infection rates in individuals who are inevitably
exposed to the contaminated water [2].
There is currently no effective vaccine against schisto-
somiasis despite the innumerable efforts for its develop-
ment in the last twenty-five years. Strong evidence
supports the possibility of development of a vaccine
against the different species of schistosomes [3,4]. Even
non-sterilizing immunity against Schistosoma is expected
to significantly reduce disease transmission and path-
ology because schistosomes do not replicate inside
human hosts [5]. However, most investigators tested po-
tential schistosomal vaccine antigens individually rather
than in properly adjuvanted antigen combinations. It is
unlikely that a single antigen would give the required
protective results due to the complex structure of the
different stages in the schistosomal life cycle besides the
multiple immune responses involved.
Several promising antigens from S. mansoni can con-
stitute the basis of a protective vaccine. The fatty-acid
binding protein (FABP), Sm14, for instance, showed
promising results in animal trials [6,7]. Sm14 is
expressed in all life stages of the S. mansoni parasite [8].
In addition, due to structural similarity to a Fasciola
hepatica antigen, Sm14 was tested as a potential vaccine
against both schistosomiasis and fascioliasis [9,10]. An-
other important antigen is the tegumental protein Sm29
which is located on the surface of adult worms and
schistosomula [11]. Interestingly, Sm29 is recognized
preferentially by IgG1 and IgG3 from putatively resistant
(PR) more than chronically infected (CI) individuals
[11]. Putatively resistant individuals are characterized by
being constantly exposed to infection but are negative
for infection for over 5 years, having never been treated
with an anthelmintic in addition to maintaining intense
cellular and humoral immune responses to crude schis-
tosomal antigenic preparations [12-15]. This, therefore,
supports the usefulness of Sm29 as a potential vaccine
candidate.
Investigators use different adjuvants in schistosomiasis
vaccine research such as complete and incomplete
Freund’s adjuvants, alum, CpG and polyinosinic-
polycytidylic acid (poly (I:C)) [11,16,17]. Although
the latter poly(I:C) adjuvant is a strong toll-like re-
ceptor 3 (TLR-3) agonist and is known to induce ap-
preciable Th1 immune response [18], it has been less
frequently used in schistosoma vaccine research than
the former adjuvants.We recently investigated the potential vaccine efficacy
of Sm14 and Sm29 mixture for protection against schis-
tosomiasis in murine model [19]. When the two antigens
were combined, they could elicit good protection where
31.2% and 40.3% reduction of adult worm burden were
attained in mice immunized with the unadjuvanted or
poly(I:C)-adjuvanted combination, respectively. However,
on a pharmaceutical scale, producing each antigen
separately then mixing them together to get the final
multi-antigen vaccine is a time- and money-consuming
process. A more practical and economic approach is to
create a fusion protein comprised of the desired antigens
so that the vaccine fusion protein can be produced in a
single biotechnology fermentation process. This clearly
cuts down the cost of large scale production where the
downstream purification procedure is carried out only
once for the fusion protein rather than performing it
twice, one for each antigen.
Consequently, in the current work, we examined the
protective vaccine efficacy of a fusion protein comprised
of the two promising schistosomal antigens Sm14 and
Sm29. The fusion protein, FSm14/29, was investigated
in Swiss albino mouse model both in an unadjuvanted
form and in combination with the synthetic poly(I:C)
adjuvant.
Methods
Vectors, culture media and incubation conditions
pQE31 vector (Qiagen GmbH, Hilden, Germany) was
used for cloning of antigen genes. Escherichia coli
TOP10 (Life Technologies Inc., New York, USA) and
E. coli M15 (pREP4) (Qiagen GmbH, Hilden, Germany)
were used as intermediate and expression hosts, respect-
ively. Luria Bertani (LB) broth and agar were used for
routine culture of E. coli strains. When required, ampi-
cillin (Amp) and kanamycin (Km) were added to culture
media at final concentrations of 100 and 25 μg/ml,
respectively.
Reverse-transcription and polymerase chain
reaction (RT-PCR)
S. mansoni adult worms were obtained from the
Schistosome Biological Supply Centre (SBSC), Theodor
Bilharz Research Institute (TBRI), Giza, Egypt. Total
RNA was extracted from the adult worms using Biozol®
(Hangzhou Bioer Technology Co., Hangzhou, China) fol-
lowing manufacturer’s instructions. Briefly, adult worms
were thoroughly cut using a scalpel, while immersed in
1 ml of Biozol® reagent. The homogenized worm suspen-
sion was subsequently vortexed in a sterile nuclease-free
microcentrifuge tube with 0.3 g acid-washed glass beads
(Sigma Aldrich, USA) for three one-minute beats with
one-minute pauses on ice in between. This was followed
by incubation on ice for 15 min and addition of 200 μL
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ously shaken for 15 s, incubated for 15 min at room
temperature and centrifuged. The upper aqueous layer
containing total RNA was subsequently treated with
DNase I then subjected to a final enrichment step to ex-
tract poly A+ mRNA by using the Oligotex® mRNA Mini
Kit (Qiagen GmbH, Hilden, Germany) following manu-
facturer’s recommendations. In brief, total RNA was
mixed with the Oligotex® resin where mRNA was cap-
tured from its poly A tail by the oligo-dT found on the
resin. The resin was washed in a spin column and bound
mRNA was subsequently eluted using the provided elu-
tion buffer.
Reverse transcription of mRNA was carried out at
42°C for 90 min using RevertAid™ H Minus First
Strand cDNA Synthesis Kit (ThermoScientific Inc.,
Vilnius, Lithuania) where Oligo (dT)18 primer was used.
PCR reactions were subsequently performed using high-
fidelity Pfu DNA polymerase (ThermoScientific Inc.,
Vilnius, Lithuania) where cDNA was used as a template
to amplify the Sm14 and Sm29 genes of S. mansoni
[Genbank accession numbers XM_002580386 and
AF029222, respectively]. Primers 5’- TAGTTTCTTG
GGAAAGTGGAA-3’ and 5’-TTAGGATAGTCGTT
TATAATTGC-3’ were used to amplify Sm14 gene
while primers 5’- GTGCGTTGCTACGTCTGTGA
TTATT-3’ and 5’-TTATTTTGTCATTCCGTTACA
TAGAT-3’ were used for Sm29 amplification. For Sm29,
we amplified the gene encoding amino acids 27–169 of
the native Sm29 to exclude the N-terminal signal pep-
tide and the C-terminal hydrophobic transmembrane
domain [20].
Creation of antigen gene fusion and cloning in E. coli
To create a fusion protein comprised of Sm14 and Sm29,
herein designated FSm14/29, the following procedure
was carried out. The above obtained Sm14 and Sm29
amplicons were used as templates for the following two
PCR reactions respectively. First, Sm14 was amplified
again using primers 5’- TGAAGGATCCGATGTCTAG
TTTCTTGGGAAAGTGGAA-3’ and 5’- ACGCGGTAC
CGGATAGTCGTTTATAATTGC-3’ with BamHI and
KpnI flanking restriction sites, respectively. Second,
Sm29 was amplified using primers 5’- TATAGGTA
CCGTGCGTTGCTACGTCTGTGATTATT-3’ and 5’-
ACGCCTGCAGTTATTTTGTCATTCCGTTACATAG
AT-3’ with flanking sites of KpnI and PstI, respectively.
Both Sm14 and Sm29 amplicons were cut with KpnI then
ligated together with T4 DNA ligase and the ligation re-
action was used as a template to amplify the fusion gene
using Sm14 forward primer and Sm29 reverse primer
with BamHI and PstI recognition sites, respectively. The
resulting fusion gene amplicon was cut with BamHI and
PstI and was ligated to a similarly digested pQE31plasmid. The resulting pQE31-(FSm14/29) was trans-
formed into E. coli TOP10 as an intermediate cloning
host. Plasmid pQE31-(FSm14/29) was subsequently ex-
tracted from E. coli TOP10 and transformed into the ex-
pression host E. coli M15 (pREP4) by electroporation
where cells were plated onto Amp/Km-containing LB
agar plates. Positive colonies were confirmed by colony
PCR to ensure correct creation of the construct. Plasmids
pQE31-Sm14 and pQE31-Sm29 containing the single
antigen genes were also created and transformed into
E. coli M15 (pREP4) using similar cloning procedures.
Figure 1A illustrates the three plasmids created in this
study.
Expression and purification of S. mansoni antigens
Fresh cultures of engineered E. coli M15 (pREP4) strains
were grown in LB broth containing Amp and Km at
37°C with vigorous shaking to an OD600 of 0.5. Protein
expression was then induced using 0.3 mM isopropyl-
β-D-thiogalactopyranoside (IPTG) for 16 h at 25°C.
His-tagged proteins were purified by metal affinity
chromatography from corresponding induced E. coli
M15 (pREP4) strains under denaturing conditions using
the procedure described by Qiagen (QIAexpressionist™).
The bound protein was eluted twice (1 ml each) in
buffer E (100 mM NaH2PO4, 10 mM Tris.Cl, 8 M
urea, pH 4.5). Aliquots of elutions were checked by
sodium dodecylsulfate-polyacrylamide gel electrophoresis
(SDS-PAGE).
Western blot was also carried out using mouse anti-
His tag antibody (Abgent Inc., San Diego, USA) as a pri-
mary antibody. Alkaline phosphatase-labeled anti-mouse
IgG antibody (KPL Inc., Maryland, USA) was used as a
secondary antibody and BCIP/NBT (KPL Inc., Maryland,
USA) was used as a phosphatase substrate. Protein elu-
tions were dialyzed against buffer containing descending
urea concentrations (6, 4, 2 and 0 M urea) and were
quantified by Bradford reagent. All purification and dia-
lysis buffers were prepared in sterile endotoxin-free
water. Absence of endotoxin in the final antigen prepar-
ation was ensured using the PYROTELL® Limulus
Amebocyte Lysate (LAL) test (Associates of CAPE
COD Inc., Massachusetts, USA) with a sensitivity level (λ)
of 0.25 EU/ml (Endotoxin unit/ml).
Animal immunization protocol
Female Swiss albino mice, 6–8 weeks old, were divided
into eight groups, ten mice each. The antigens FSm14/
29, Sm14 and Sm29 were administered, in the presence/
absence of poly(I:C) adjuvant (Invivogen, Toulouse,
France), intraperitoneally (IP) to mice in corresponding
groups on days 1, 14 and 28. FSm14/29, Sm14 and
Sm29 were given at doses of 20, 20 and 10 μg/mouse re-
spectively while the poly(I:C) adjuvant was given at a
Figure 1 Illustration of the created plasmids and purified antigens described in the study. (A) Schematic representation of the construction of
pQE31-FSm14/29, pQE31-Sm14 and pQE31-Sm29. Amp: β-lactamase coding sequence; ColE1: ColE1 origin of replication; PT5: T5 promoter; lac O: lac
operator element; RBS: Ribosomal Binding Site; H: Hexahistidine tag; MCS: Multiple Cloning Site; T: Terminator; B: BamHI recognition site;
K: KpnI recognition site; P: PstI recognition site. (B) SDS-PAGE of antigens purified from corresponding induced E. coli M15 (pREP4) strains. Lane 1,
protein ladder; lanes 2 and 3, two successive elutions of the fusion antigen FSm14/29; lanes 4 and 5, two successive elutions of Sm14 antigen; lanes
6 and 7, two successive elutions of Sm29 antigen. Buffer E (pH 4.5) was used for elutions under denaturing conditions following induction with
0.3 mM IPTG at 25°C for 16 h.
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based on previously published data for Sm14 and Sm29
[21,22]. Two negative control groups injected with
sterile saline or poly(I:C) adjuvant were also included.
All antigen doses were prepared in sterile endotoxin-
free saline. Two weeks after the last booster, serum
samples were collected and mice were challenged
with S. mansoni cercariae. Each mouse was infected
with 100 cercariae as previously described [23,24].
Animals were euthanized seven weeks postinfection
and different parasitological parameters were evaluated.
Two independent vaccine trials were carried out. All
animal experiments and procedures were approved
by the animal ethics committee of Alexandria University
(licence no. 04085) based on national regulations for ani-
mal experimentation.Determination of antigen-specific serum IgG1 and IgG2a
using enzyme-linked immunosorbent assay (ELISA)
Antigen-specific immunoglobulins IgG1 and IgG2a
were determined in serum samples from mice two
weeks after the last vaccine booster as previously de-
scribed [25] with slight modification. Briefly, an ELISA
assay was developed where ELISA plates (Greiner Bio-
One, Frickenhausen, Germany) were coated with 100 μl
of individual antigens at a final concentration of 10 μg/ml.
Serum dilutions were added to the plates after blocking
with 5% skimmed milk in phosphate-buffered saline
(PBS). A His-tagged irrelevant antigen, listeriolysin O
[26], was used as a negative control in the ELISA test
in order to exclude any probable reactivity against the
His-tag itself. Plates were subsequently washed and
peroxidase-labeled goat anti-mouse IgG1 or anti-mouse
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added for 1 h. Following extensive washing, the sub-
strate 3,3’,5,5’-tetramethylbenzidine (TMB) was added to
the wells followed by 1 M sulfuric acid to stop the re-
action. Absorbance readings were measured at 450 nm
in a microplate reader (Biotek, Winooski, USA).
Evaluation of parasitological parameters in
challenged mice
The following parasitological parameters were assessed
in euthanized animals.
i) Estimation of the adult worm load and
microscopical examination
Hepatic and porto-mesenteric vessels were perfused
and adult worms were recovered and counted [24].
The protection level was evaluated based on the
percentage reduction (R) as follows: R = [(C-V)/C]
X100, where C is the mean worm count in the
negative control group and V is the mean worm
count in vaccinated groups [23,24]. Recovered
worms were processed as previously described
[27,28] for carmine staining and for examination
by scanning electron microscopy (SEM).
ii) Examination of tissue egg loads
Livers and intestines of both the vaccinated and
control animal groups were isolated and weighed.
Eggs were counted per gram tissue according to the
method described by Cheever [29].
iii)Histopathological examination of livers
Livers of mice from all studied groups were
subjected to histopathological examination following
hematoxylin and eosin (H&E) and Masson’s
Trichrome (MT) staining [30]. Pathological changes
in the hepatic parenchyma were examined and the
granulomata mean number and diameters were
determined [31].
Statistical analysis
Data were statistically analyzed with the ANOVA test
followed by post-hoc Tukey-Kramer test using GraphPad
InStat version 3.1 software. Results with p value < 0.05
were considered statistically significant.
Results
Recombinant expression and detection of antigens
The DNA sequence of all created constructs was deter-
mined (GATC Biotech, Cologne, Germany) and was
found to be identical to the database of target accession
numbers through sequence alignment. Proper antigen
production by induced E. coli M15 (pREP4) strains was
confirmed by SDS-PAGE (Figure 1B) and Western blot
(data not shown).Antigen-specific serum antibodies
Serum samples were collected from immunized mice
two weeks after the last booster for specific antibody de-
tection by ELISA. The single antigens Sm14 and Sm29
elicited specific IgG1 antibodies in immunized mice
mainly in groups vaccinated with corresponding adju-
vanted antigens when compared with the negative con-
trol and poly(I:C) groups (Figure 2A and B). The fusion
antigen FSm14/29 stimulated significant specific IgG1 in
animals immunized with unadjuvanted or poly(I:C)-
adjuvanted fusion antigen when compared with the
negative control and poly(I:C) groups (Figure 2C). Upon
comparing the results of IgG1 against FSm14/29 and the
individual antigens, it was found that anti-Sm14 IgG1
antibodies (mean absorbance 0.95) was significantly
higher (p = 0.03) than anti-FSm14/29 IgG1 (mean ab-
sorbance 0.67) in groups immunized with the poly(I:C)-
adjuvanted corresponding antigens (Figures 2A and C).
On the other hand, specific IgG2a antibody levels were
not statistically significant in all mice groups except for
the poly(I:C)-adjuvanted Sm14 vaccinated group when
compared to the saline-treated negative control group
(Figure 2D-F). The mean absorbance values for IgG2a
ELISA detection were generally higher in mice immu-
nized with poly(I:C)-adjuvanted antigens than in mice
immunized with unadjuvanted antigens, but difference
was not statistically significant (Figure 2D-F).
Protection against S. mansoni infection in mice
immunized with the fusion antigen
Groups immunized with FSm14/29 or the poly(I:C)-
adjuvanted FSm14/29 showed significant reduction of
adult worm burden of 44.7 and 48.4% respectively
(Table 1). On the other hand, total adult worm burden
was not significantly reduced in mice immunized with
the single antigens when compared with the negative
control group. As regards the liver egg burden, the most
significant reductions, 82.8 and 73.5%, were achieved in
mice immunized with poly(I:C)-adjuvanted and unadju-
vanted fusion protein, respectively (Table 1). Similarly,
the intestinal egg count was minimal in mouse groups
immunized with the fusion protein where burden reduc-
tion reached 72.8 and 76.6% for the adjuvanted and
unadjuvanted FSm14/29 antigen, respectively (Table 1).
All percentage reduction values were calculated relative
to the infected saline-injected (unimmunized) negative
control group. Importantly, the adult worm burden and
tissue egg loads were statistically lower in groups immu-
nized with the adjuvanted or unadjuvanted FSm14/29
(p < 0.05) when compared with all other groups in-
cluding groups immunized with the individual anti-
gens, the saline negative control and the adjuvant
groups. However, there was no statistically significant
difference between the groups immunized with either
Figure 2 Antigen-specific IgG1 and IgG2a antibodies in sera of immunized mice. ELISA plates were coated with corresponding antigens
and serum samples were tested for the presence of anti-antigen IgG1 (A, B and C) and anti-antigen IgG2a (D, E and F). The shown results are at
1/250 serum dilution where error bars represent the mean reading +/− SE (standard error of the mean). (*) p < 0.05; (**) p < 0.01; (***) p < 0.001
by the ANOVA test and post-hoc Tukey-Kramer test. Asterisks are shown only for groups that showed significant statistical difference.
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vanted FSm14/29 concerning the reduction of adult
worm and tissue egg burdens.
Alterations in adult worms detected by light microscopy
Adult worms obtained from mice immunized with
the unadjuvanted or poly(I:C)-adjuvanted FSm14/29
showed noticeable deformities. These include tegu-
mental irregularities and occasional swollen knots as
shown in details in Figure 3 which shows representa-
tive pictures for worms recovered from the infected
FSm14/29-immunized group. None of these observed
deformities were detectable in adult worms recovered
from all other experimental groups including the in-
fected unvaccinated negative control group, the adjuvant
group and groups immunized with the individual anti-
gens. In addition, we found that both male and female
adult worms recovered from mice previously immunizedwith adjuvanted or unadjuvanted FSm14/29 showed sta-
tistically significant reduction (p <0.05) in their perime-
ters when compared with the negative control group
(data not shown).
Alterations in adult worms as determined by scanning
electron microscopy (SEM)
Since FSm14/29, whether adjuvanted or unadjuvanted,
showed the best protection results against S. mansoni
infection (Table 1), we decided to further examine the
ultrastructural changes of the adult worms recovered
from groups immunized with FSm14/29 using SEM.
Male adult worms obtained from unimmunized
control mice showed normal configuration and tegu-
mental structure, with evident normal spines on the
dorsal surface behind the beginning of the gyneco-
phoric canal (Figure 4A). The dorsolateral surface of
the mid-body was covered by tubercles of uniform
Table 1 Assessment of different parasitological parameters and protective efficacy in pre-immunized mice challenged with S. mansoni cercariae
Animal group Adult worm
burden ± SE
%R Eggs/gram liver ± SE %R Eggs/gram intestine ± SE %R Mean no. of
granulomas/LPF ± SE
%R Mean granuloma
diameter (μm) ± SE
%R
Negative control 22.714 ± 2.6 - 2489.857 ± 172 - 3803.571 ± 352.4 - 10.714 ± 0.5 - 285.857 ± 12.1 -
Poly (I:C) 21.778 ± 2.4 4.1NS 1918.556 ± 220 22.9NS 3586.444 ± 181.6 5.7NS 8.444 ± 0.5 21.2† 254.444 ± 10.1 11NS
Sm14 22.1 ± 1.9 2.7NS 2452.2 ± 167.2 1.5NS 3806.1 ± 195.5 0.1NS 7.8 ± 0.29 27.2** 216.778 ± 6.8 25**
Sm14+ poly (I:C) 19.429 ± 3.1 14.5NS 1878.571 ± 104 24.6NS 2702 ± 158.6 28.96† 8 ± 0.58 25.33* 227.857 ± 11.3 20.3*
Sm29 18.625 ± 2 18NS 1489.5 ± 97.1 40.2* 2604.875 ± 132.1 31.5* 7.375 ± 0.46 31.2** 219.375 ± 7.9 23.3**
Sm29+ poly (I:C) 21.222 ± 1.5 6.6NS 2042.111 ± 230 18NS 3502.889 ± 219 7.91NS 7.556 ± 0.5 29.5** 240 ± 10.1 16†
FSm14/29 12.556 ± 1.2 44.7† 659.222 ± 116.5 73.5** 888.667 ± 89.3 76.64** 4.1 ± 0.23 61.7** 152.556 ± 7.7 46.6**
FSm14/29 + poly(I:C) 11.714 ± 1.7 48.4† 428.857 ± 103.6 82.8** 1033.857 ± 128.4 72.82** 3 ± 0.31 72** 102.571 ± 6.4 64.1**
(NS): statistically non-significant; (†): p value < 0.05; (*): p value < 0.01; (**): p value < 0.001 when compared to the negative control group using the ANOVA test with post-hoc Tukey-Kramer test. SE: standard error of the
mean. LPF: low power field. %R: percentage reduction as compared to the negative control. All results shown for groups immunized with adjuvanted or unadjuvanted FSm14/29 were significantly different (p < 0.05)














Figure 3 Light microscopic appearance of carmine-stained adult worms recovered from FSm14/29-immunized mice. (A) Abnormally
shortened adult male worm exhibiting multiple gut dilatations (Gd). The testes were not clearly seen due to dilatations of the gut in the anterior
part of the worm. (B) Slightly elongated male with bulging (arrow) in the posterior end. (C&D) Male worm demonstrating gut dilatation which
hides the appearance of the testes, with ill-defined oedematous suckers, and remarkable tegumental irregularities in the worm outline. (E) An
example of an elongated female. (F&G) Posterior ends of females possessing universal pronounced tegumental oedematous irregularities (arrows)
or even wrinkled posterior ends. (H) Occasional swollen knots (Kn) in a female mid-body. Sparseness of the pigment content of the gut was
noticed in all examined female worms with indistinct vitelline gland lobulations and ill-defined ovarian boundaries.
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Figure 4 Scanning electron micrographs of adult S. mansoni male worms recovered from unimmunized group (A and B) and from
FSm14/29-immunized group (C-H). (A) A male worm obtained from infected control group showing normal body configuration, typical
oral and ventral suckers, and distinct tegumental structure with evident normal spines on the dorsal surface behind the beginning of the
gynecophoric canal (Gc), X200. (B) Tegument of the middle dorsolateral region showing numerous large tubercles, each bearing numerous
spines. Intertubercular ridges and ciliated sensory papillae are obvious, X 5,000. (C) Tegumental surface alterations in adult male from infected
FSm14/29-immunized group demonstrating widening of the gynecophoric canal (Gc), loss of some areas of the tegumental tubercles and ridges
(arrows), surface erosions (Er), tegumental tear (Tt), and bossing of the terminal end of the worm, X200. The posterior end shows several areas of
bulging. (D) Higher magnification of a conspicuously widened gynecophoric canal, along with restricted spine loss (arrow), X5,000. (E) Swollen
area between the oral and ventral suckers showing circumferentially arranged ridges with sensory papillae rows. An evident dorsal dimple is
witnessed (Dp), along with suckers oedema and blebbing, X2,000. (F) Eminent flattening of the dorsal tubercles along with shortened spines
which were irregularly positioned or even lost in some areas (arrows), X5,000. (G) Altered dorsal tubercles revealed peeling and focal sloughing
(Sl) of their tegument. Tubercular and inter-tubercular coarse bumpy tegumental irregularities were observed, with occasional burst of some
blistered tubercles, X5,000. (H) Host leucocytic (arrows) attachment to the worm surface with evident spine blunting, X7500.
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interspaced with tegumental ridges and ciliated sen-
sory papillae (Figure 4B).
On the contrary, SEM examination of male worms
recovered from mice immunized with unadjuvanted
or poly(I:C)-adjuvanted FSm14/29 showed marked
extensive tegumental alterations. These appeared in the
form of conspicuous widening of the gynecophoric canal
in a considerable number of the examined worms
(Figure 4C and D). Swelling and small sized blebbings in
the lips of the suckers were also present (Figure 4E).
Worms exhibited eminent flattening of their dorsal tu-
bercles along with shortened spines which were irregu-
larly positioned or even lost in some areas (Figure 4F).
Furthermore, altered dorsal tubercles revealed peeling
and focal sloughing of their tegument, in association with
tubercular and inter-tubercular coarse bumpy tegumental
irregularities, with occasional burst of some blistered
tubercles (Figure 4G). Host leucocytic attachment to
the worm surface was a commonly witnessed feature
(Figure 4H).
Figure 5 shows representative SEM images of female
worms obtained from control unimmunized mice and
from mice immunized with the fusion protein. The
tegumental surface of female worms isolated from
unimmunized mice was generally smooth with fine cir-
cular ridges interspaced with regular clefts and was car-
rying conspicuous sensory bulbs throughout the dorsal
surface (Figure 5A). On the other hand, adult female
worms obtained from FSm14/29-immunized mice ex-
hibited drastic alterations in the form of extensive
swelling of the forebody tegument associated with
edema and small-sized blebbings in the lips of their
suckers. Spines lining the suckers were short, irregularly
positioned and chubby in appearance (Figure 5B). Fur-
thermore, females were convoluted expressing irregu-
larly positioned constrictions in various areas of their
bodies (Figure 5C). Their surfaces showed swellings
alternating with dimples and depressions, gappings, and
wrinkling (Figure 5D). Higher magnification verified
that the linear transverse tegumental ridges encircling
the worm body were not observable, being replaced by
swelling induced loosing of the clefts, and fusions of
ridges. This resulted in the formation of long irregular
and disorganized splits (Figure 5E). Similar to altered
males, it was highly evident that host leucocytes were
attached to the body of the female worms in various
areas (Figure 5F).
Histopathological changes
All immunized groups showed significant reduction in
both number and size of liver granulomata when compared
with the negative control group (Table 1). Groups immu-
nized with the unadjuvanted or poly(I:C)-adjuvantedfusion protein showed the most significant reduction in
mean granuloma number per low power field of 61.7 and
72% respectively when calculated with respect to the sa-
line negative control group. In addition, percentage re-
duction of mean granuloma diameter of these two
previous groups was 46.6 and 64.1% respectively when
calculated with respect to the saline negative control
group. It is important to note that the granuloma number
and diameters in the groups immunized with adju-
vanted or unadjuvanted FSm14/29 were statistically
lower (p <0.001) than all other groups immunized with
the single antigens, the saline negative control group and
the adjuvant group. It is also noteworthy that reduction
in the mean granuloma diameter was statistically sig-
nificant (p < 0.01) in mice immunized with poly(I:C)-
adjuvanted FSm14/29 when compared with those
immunized with the unadjuvanted fusion protein.
Liver sections of unimmunized infected control group
showed typical histopathological features as shown in
Figure 6A-E. Abundant large irregular cellular granu-
lomata, in which S. mansoni eggs were surrounded
mainly by epithelioid cells and infiltrating lympho-
cytes were observed with no sign of formation of col-
lagen fibers. In groups immunized with unadjuvanted or
poly(I:C)-adjuvanted FSm14/29, fewer and smaller cellu-
lar granulomata were seen and parenchymal changes
were milder than controls (Figure 6F-J). Degenerated
eggs were surrounded mostly by numerous eosinophils,
neutrophils, lymphocytes and few epithelioid cells with
evident fibroblastic proliferation (Figure 6 I and J).
Discussion
We recently reported the beneficial effects of combining
Sm14 and Sm29 antigens for vaccination against S. man-
soni [19]. The mixture of those two antigens adjuvanted
with poly (I:C) could produce significant reduction in
adult worm burden (40.3%), liver egg burden (68.2%)
and intestinal egg burden (57.9%) in immunized mice
[19]. In the current study, we tested a fusion protein
comprised of Sm14 and Sm29 for potential vaccine pro-
tective efficacy against schistosomiasis. The use of
FSm14/29 is a more cost-effective approach upon large
scale pharmaceutical production of the vaccine. A simi-
lar approach is used in the commercial production of in-
sulin by E. coli where the proinsulin molecule, that
contains the two peptide chains of insulin, is produced
at large scale. This latter method is widely used now-
adays instead of the old method that involved producing
the two insulin peptide chains separately in E. coli then
combining them [32].
Investigational vaccines against S. mansoni are more
likely to succeed if they can elicit robust immune re-
sponses against multiple antigenic targets in the schisto-
somes. Animals immunized with either unadjuvanted or
Figure 5 Scanning electron micrographs of adult S. mansoni female worms recovered from unimmunized group (A) and from
FSm14/29-immunized group (B-F). (A) The dorsolateral surface of a female recovered from the unimmunized control group showing fine
circular ridges interspaced with regular clefts and carrying conspicuous sensory bulbs (Sb), X3,500. (B) The anterior end of a female worm recovered
from FSm14/29-immunized animals exhibiting extensive swelling of the forebody tegument, with evident strangulation (thick arrow), associated with
small sized blebbings (Bl) in the lips of their suckers. Spines lining the edematous suckers were short, irregularly positioned and chubby in appearance
(thin arrow), X500. (C) A convoluted female expressing irregularly positioned constrictions in various areas of its body (arrows), besides loss of the
mid-body circular ridges with complete destruction of the external surface of the forebody, X750. (D) Kinky female surface swellings alternating
with dimples (Dp), furrows (Fr), gappings (Ga), and wrinkling (Wr), X750. (E) Higher magnification verifying that the linear transverse tegumental
ridges encircling the body worm were replaced by swelling induced loosing of the clefts, and fusions of ridges. This resulted in the formation of
long irregular and disorganized splits, X3,500. (F) Host leucocytes attached to the tegument of the female surfaces (arrows), X7,500.
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reduction of adult worm burden, respectively. Further-
more, significant reduction of tissue egg burden andgranulomata was also achieved. The protective results
shown in this study for FSm14/29, whether adjuvanted
or not, were slightly higher than what we previously
Figure 6 (See legend on next page.)
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Figure 6 Liver histological sections form infected unimmunized control mice (A-E) and FSm14/29-immunized mice (F-J). (A) Liver
section of infected unimmunized mouse showing Kupffer cells’ hyperplasia (H&E x100). (B) Liver section of an infected mouse showing hydropic
degeneration and ballooning of hepatic cells (H&E x400). (C) Liver section of an infected mouse showing lymphocytic infiltration of portal tract
with marked dilatation and proliferation of blood vessels (H&E x100). (D) Liver section of an infected mouse showing numerous large size cellular
granulomata (H&E x100). (E) Liver section of an infected mouse showing non-degenerated well developed S. mansoni egg trapped within cellular
granuloma (MT x400). (F) Liver section of infected FSm14/29-immunized mouse showing decreased number and size of cellular granulomata
surrounding degenerated eggs (H&E x100). (G) Liver section of infected FSm14/29-immunized mouse showing lesser degree of cellular swelling
and inflammatory infiltration (H&E x400). (H) Liver section of infected FSm14/29-immunized mouse showing regenerative activity represented by
hepatocyte binucleation (arrows) (H&E x400). (I & J) Liver sections of infected FSm14/29-immunized mouse showing small well-circumscribed
fibrous granulomata with degenerated eggs (MT X400).
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This demonstrates the potential value of FSm14/29 fu-
sion protein as a cost-effective and efficacious vaccine
candidate when compared with the combination of
Sm14 and Sm29.
Under the experimental conditions of our study,
poly(I:C)-adjuvanted or unadjuvanted individual Sm14
and Sm29 antigens did not produce statistically signifi-
cant reduction in adult worm burden when compared
with the negative control group (Table 1). Upon review-
ing the literature, we found that different experimental
conditions, different adjuvants and variable vaccine pro-
tective results were reported for Sm14 and Sm29. As
regards Sm14, vaccine protection results ranged from
lack of protection to variable degrees of protection.
When mice were immunized with Sm14 adjuvanted with
alum hydroxide, no reduction in adult worm burden was
observed by Fonseca and colleagues although high levels
of antigen-specific IgG1 were observed [33]. In addition,
oral immunization with Salmonella harboring an Sm14-
based DNA vaccine did not result in any reduction of
adult worm burden in immunized mice [34]. Further-
more, intranasal administration of Sm14 or Sm14 fused
to cholera toxin subunit B (CTB) failed to produce sig-
nificant protection against S. mansoni infection in BALB/
c mice [35]. Nevertheless, different protection levels were
reported in animals immunized with Sm14 ranging from
25% to 67% [10,22,33]. Concerning the schistosomal anti-
gen Sm29, 51% reduction in adult worm burden was
observed in C57BL/6 mice immunized with Sm29 adju-
vanted with complete and incomplete Freund’s adjuvants
[11]. When C57BL/6 mice were immunized with a mix-
ture of tegumental proteins composed mainly of Sm200
and Sm29, only 42% reduction of adult worm burden was
achieved [36]. More recently, C57BL/6 mice immunized
with Sm29 plus CpG/alum mixture showed only 20.36%
reduction of adult worm burden [17]. Moreover, in the
same study, immunization with two chimeric vaccine
candidates composed of the two schistosomal antigens
Sm29 and SmTSP-2 resulted in protection levels ranging
from 27.84 to 34.83% [17]. This apparent discrepancy
seen in the literature can be attributed to the differentexperimental conditions used by different research
groups. Indeed, different adjuvants, routes of administra-
tion, antigen doses, vaccination regimens and even
mouse strains were used by different investigators. This
renders the direct comparison between published data
unfeasible and results should be assessed based on the
pertinent experimental conditions.
In the present study, we tested the fusion protein
FSm14/29 in the presence and absence of poly(I:C) adju-
vant. Poly(I:C) is reported to induce T helper type 1
(Th1) immune response with high levels of IFN-γ and
IgG2a [16,37]. Th1 immune response is reported to
be protective against murine schistosomiasis [33].
Both IgG1 and IgG2a antibodies were observed against
FSm14/29 especially in mice immunized with the
poly(I:C)-adjuvanted fusion protein. However, anti-
FSm14/29 IgG2a levels were not statistically significant
(Figure 2F). It was previously reported that IgG1 and IL-
10-mediated immune responses downregulate the granu-
lomatous hypersensitivity reaction of schistosomiasis
[38]. This fits well with the reduction of granulomata size
and number observed in mice immunized with unadju-
vanted or poly(I:C)-adjuvanted FSm14/29. Indeed, high
levels of specific IgG1 antibodies against Sm14 and Sm29
were detected in the sera of individuals resistant to schis-
tosomiasis in endemic areas [20,39]. Although poly(I:C)
is known to induce Th1-biased immune response, Zhou
and coworkers found that poly(I:C) can induce a T helper
type 2 (Th2) response in non-obese diabetic mice upon
long-term administration [40]. Commercial poly(I:C) ad-
juvant has different molecular weights ranging from 0.2
to 8.5 kb depending on the supplier. In our study, we
used high molecular weight (HMW) poly(I:C) (1.5-8 kb)
purchased from Invivogen. It was reported that the mo-
lecular weight of poly(I:C) has a significant impact on its
immunomodulatory actions leading sometimes to oppos-
ite effects on immune cells [41]. In addition, some inves-
tigators use the more stable poly ICLC, which is poly(I:C)
stabilized with poly-lysine and carboxymethylcellulose, in
their experiments in order to obtain robust results [42].
All these factors are under investigation in order to deter-
mine the optimum conditions required to maximize
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cytokine profile following vaccination would certainly
help in choosing the most suitable grade of poly(I:C).
Doubling the poly(I:C) adjuvant dose from 50 to100 μg
per mouse is another option which might enhance
its Th1 effects. In fact, the manufacturer of poly(I:C)
used in our experiments (Invivogen; www.invivogen.com)
recommends a dose range of 10–100 μg of adjuvant per
mouse.
It is also noteworthy that there were significant levels
of IgG1 against Sm14 and Sm29 besides FSm14/29
(Figure 2A-C). Nevertheless, protection was pronounced
only in groups immunized with FSm14/29. This finding
indicates that IgG1 role in protection against schisto-
somiasis is only partial and Th1 cell-mediated immune
response might be required [33].
In the present study, there has been interestingly a
significant reduction in the liver and intestinal egg
burden in groups immunized with the unadjuvanted
or poly(I:C)-adjuvanted FSm14/29 (Table 1). These
results may indicate either an anti-fecundity effect of
the vaccine or merely a delayed inception of egg laying
[43]. Generation of developmental oograms and examin-
ation of egg laying at different experimental intervals
should be performed to clarify this point [43,44].
Morphological alterations of adult worms give an indi-
cation of strong immune responses elicited by tested
vaccines. The morphological changes noticed here are
probably because the two antigens used in this study are
easily accessed by the host immune system. Sm14 is a
FABP localized in tissues near the interfaces of host/
parasite contact including the basal lamella of the tegu-
ment [8], while Sm29 is a tegumental protein located on
the surface of adult worms and schistosomula [11].
Immunization with the fusion protein FSm14/29, which
is composed of a crucial couple of antigens, primed the
immune system against the challenge infection resulting
in tegumental changes as verified by the SEM study.
Abdeen and coworkers immunized rabbits with irradi-
ated S. mansoni cercariae and used the rabbits’ serum to
passively immunize mice infected with S. mansoni. They
observed similar tegumental damage and ultrastructural
changes in S. mansoni adult worms recovered from in-
fected mice [45].
In our study, scanned convoluted adult worms exhibited
drastic tegumental and sucker alteration, with noticeable
host leucocytic attachment to their surfaces. Conspicuous
widening of gynecophoric canals of some males has prob-
ably hindered their appropriate coupling with females. It is
well reported that muscular action of the clasping male
helps females to get blood nutrition from the host [46]. In
addition, decoupling has other negative effects on females
because males are responsible for physically transporting
the females and fertilizing oocytes [47].Breaking and erosion of tubercles and ridges of adult
worms recovered from FSm14/29-immunized mice were
evident in our study. This exposed the basal lamina and
eventually resulted in focal sloughing of the tegument.
Such drastic tegumental changes practically expose more
underlying antigenic determinants to the host immune
recognition and effector functions culminating in en-
hanced vaccine protective efficacy.
Since most chronic morbidity features of schistosomia-
sis are related to the egg formation rather than the adult
worms, minimizing tissue egg loads and granuloma for-
mation would be a desirable goal of any successful vac-
cine against S. mansoni. The fusion protein FSm14/29,
whether unadjuvanted or poly(I:C)-adjuvanted, showed
significant reduction in both granulomata number and
size in challenged immunized mice. Diminished granu-
loma size may suggest an effect on the immune response
around the parasite ova in the tissues. Moreover, the
granulomata showed proliferation of fibrocytes and in-
crease in the amount of fibrous tissue that was obviously
seen in Masson’s trichrome (MT)-stained sections sug-
gesting that there is an attempt of tissue healing.Conclusion
Overall, we have demonstrated that vaccination with the
fusion protein FSm14/29 offers significant protection
against S. mansoni infection in Swiss albino mice.
Immunization resulted in significant reduction of adult
worm burden, tissue egg loads and liver granuloma
formation. Deleterious structural changes were also ob-
served in adult worms recovered from immunized mice.
Optimization of experimental conditions and the adju-
vant used should greatly improve the protection outcome
and consolidate the concept of using multi-antigen fusion
proteins as vaccine candidates against S. mansoni.
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